HUE052864T2 - Nyújtott leadású risperidon mikrogömb készítmény - Google Patents
Nyújtott leadású risperidon mikrogömb készítményInfo
- Publication number
- HUE052864T2 HUE052864T2 HUE19176691A HUE19176691A HUE052864T2 HU E052864 T2 HUE052864 T2 HU E052864T2 HU E19176691 A HUE19176691 A HU E19176691A HU E19176691 A HUE19176691 A HU E19176691A HU E052864 T2 HUE052864 T2 HU E052864T2
- Authority
- HU
- Hungary
- Prior art keywords
- sustained release
- release microsphere
- microsphere composition
- risperidone sustained
- risperidone
- Prior art date
Links
- 239000004005 microsphere Substances 0.000 title 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title 1
- 229960001534 risperidone Drugs 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110102840 | 2011-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE052864T2 true HUE052864T2 (hu) | 2021-05-28 |
Family
ID=47071591
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16179390A HUE046004T2 (hu) | 2011-04-25 | 2012-04-10 | Risperidon nyújtott hatóanyagleadású mikroszféra készítmény |
| HUE19176691A HUE052864T2 (hu) | 2011-04-25 | 2012-04-10 | Nyújtott leadású risperidon mikrogömb készítmény |
| HUE12777430A HUE032310T2 (hu) | 2011-04-25 | 2012-04-10 | Nyújtott risperidon-leadású mikrogömb kompozíció |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16179390A HUE046004T2 (hu) | 2011-04-25 | 2012-04-10 | Risperidon nyújtott hatóanyagleadású mikroszféra készítmény |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12777430A HUE032310T2 (hu) | 2011-04-25 | 2012-04-10 | Nyújtott risperidon-leadású mikrogömb kompozíció |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9446135B2 (hu) |
| EP (4) | EP2701687B1 (hu) |
| JP (2) | JP5728128B2 (hu) |
| KR (2) | KR101932207B1 (hu) |
| CN (2) | CN104127385B (hu) |
| AU (1) | AU2012248038B2 (hu) |
| BR (1) | BR112013027235B1 (hu) |
| CA (1) | CA2832663C (hu) |
| ES (4) | ES2855349T3 (hu) |
| HK (1) | HK1185560A1 (hu) |
| HU (3) | HUE046004T2 (hu) |
| PL (4) | PL2701687T3 (hu) |
| PT (3) | PT2701687T (hu) |
| RU (1) | RU2586306C2 (hu) |
| WO (1) | WO2012146052A1 (hu) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2832663C (en) | 2011-04-25 | 2016-02-09 | Shandong Luye Pharmaceutical Co., Ltd. | Risperidone sustained release microsphere composition |
| CN103990114B (zh) * | 2014-05-06 | 2016-05-18 | 浙江圣兆药物科技股份有限公司 | 一种艾塞那肽缓释微球组合物 |
| JP2016102093A (ja) * | 2014-11-28 | 2016-06-02 | ニプロ株式会社 | 塩基性の求核化合物を含有するマイクロカプセルの製造方法 |
| US20190029969A1 (en) * | 2015-09-07 | 2019-01-31 | Nipro Corporation | Risperidone-containing microcapsule, method for preparing same and release control method |
| CN105560192A (zh) * | 2016-01-07 | 2016-05-11 | 万全万特制药江苏有限公司 | 一种棕榈酸帕利哌酮长效微球注射液的制备方法 |
| WO2018015915A1 (en) | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
| CN106390102A (zh) * | 2016-11-30 | 2017-02-15 | 郑州仁宏医药科技有限公司 | 一种治疗精神分裂症的西药组合物 |
| CN106727589A (zh) * | 2017-01-24 | 2017-05-31 | 广州帝奇医药技术有限公司 | 帕利哌酮及其衍生物的缓释组合物与该缓释组合物的制备方法 |
| CN106822042A (zh) * | 2017-01-24 | 2017-06-13 | 广州帝奇医药技术有限公司 | 一种利培酮缓释组合物及其制备方法 |
| CN116270486A (zh) * | 2017-01-24 | 2023-06-23 | 广州帝奇医药技术有限公司 | 水难溶或微溶性药物缓释组合物及其制备方法 |
| CN106822043A (zh) * | 2017-01-24 | 2017-06-13 | 广州帝奇医药技术有限公司 | 利培酮缓释组合物及其制备方法 |
| CN106963746A (zh) * | 2017-03-17 | 2017-07-21 | 广州帝奇医药技术有限公司 | 一种水难溶/微溶性药物缓释组合物 |
| CN107349175A (zh) * | 2017-06-06 | 2017-11-17 | 浙江理工大学 | 一种负载脂肪褐变剂的微针贴片及其制备方法 |
| CN107049985B (zh) * | 2017-06-07 | 2020-06-19 | 广州帝奇医药技术有限公司 | 一种抗帕金森病药物的长效缓释制剂及其制备方法 |
| CN107213136B (zh) * | 2017-06-07 | 2021-06-01 | 广州帝奇医药技术有限公司 | 一种长效缓释药物制剂及其制备方法 |
| CN107412188A (zh) * | 2017-09-06 | 2017-12-01 | 广州中医药大学 | 阿塞那平微球及其制备方法和其注射剂 |
| CN112545995B (zh) * | 2018-05-16 | 2024-02-23 | 珠海市丽珠微球科技有限公司 | 一种阿立哌唑缓释微球及其制备方法 |
| CN108635339B (zh) * | 2018-08-06 | 2021-07-06 | 深圳市泛谷药业股份有限公司 | 一种利培酮植入剂及其制备方法 |
| GR1009870B (el) * | 2019-07-09 | 2020-11-12 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει ενα ατυπο αντιψυχωσικο φαρμακο και μεθοδος παρασκευης αυτου |
| JP2023508527A (ja) * | 2019-12-31 | 2023-03-02 | 広州帝奇医薬技術有限公司 | 第３級アミン医薬組成物およびその工業化バッチ調製方法 |
| CN115006354A (zh) * | 2022-06-16 | 2022-09-06 | 北京阳光诺和药物研究股份有限公司 | 一种利培酮-共混plga缓释微球及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| ES2077547T3 (es) * | 1992-11-17 | 2000-06-16 | Yoshitomi Pharmaceutical | Microesfera de liberacion sostenida que contiene un antipsicotico y procedimiento de produccion. |
| NZ276088A (en) | 1993-11-19 | 1999-07-29 | Janssen Pharmaceutica Nv | [(1,2-benzisoxazol-3-yl)-1-piperidinyl-alkyl-6,7,8,9-tetrahydro-4h- pyrido[1,2-a]-pyrimidin-4-one derivatives (ie risperidone) |
| US6558702B2 (en) * | 2001-04-13 | 2003-05-06 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
| US7368126B2 (en) * | 2002-11-06 | 2008-05-06 | Guohua Chen | Controlled release depot formulations |
| WO2004094414A1 (en) | 2003-04-22 | 2004-11-04 | Synthon B.V. | Water soluble salts of risperidone |
| ES2527286T3 (es) * | 2004-04-30 | 2015-01-22 | Abraxis Bioscience, Llc | Microesferas de liberación sostenida y métodos de fabricación y uso de las mismas |
| ES2317138T3 (es) * | 2004-11-22 | 2009-04-16 | Hisamitsu Pharmaceutical Co., Inc. | Parche transdermico que comprende un agente de diminucion del punto de fusion. |
| ES2755032T3 (es) * | 2005-12-22 | 2020-04-21 | Novartis Ag | Formulación de liberación sostenida que comprende octreótido y dos o más polímeros de poliláctido-co-glicólido |
| CN101292960B (zh) | 2006-04-29 | 2011-02-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 含利培酮的缓释微球及其制备方法 |
| AR066677A1 (es) | 2007-05-24 | 2009-09-02 | Novartis Ag | Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas. |
| MX354603B (es) | 2007-05-25 | 2018-03-13 | Indivior Uk Ltd | Formulaciones de transferencia sostenida de compuestos de risperidona. |
| JP5222550B2 (ja) * | 2007-12-27 | 2013-06-26 | 財團法人工業技術研究院 | 徐放性組成物およびその製造方法 |
| CN101653422B (zh) | 2008-08-20 | 2013-03-20 | 山东绿叶制药有限公司 | 利培酮缓释微球、其制备方法和用途 |
| CN101584652B (zh) | 2009-06-19 | 2012-06-20 | 上海医药集团股份有限公司 | 利培酮缓释凝胶注射剂及其制备方法 |
| UA111162C2 (uk) | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
| CA2832663C (en) | 2011-04-25 | 2016-02-09 | Shandong Luye Pharmaceutical Co., Ltd. | Risperidone sustained release microsphere composition |
-
2012
- 2012-04-10 CA CA2832663A patent/CA2832663C/en active Active
- 2012-04-10 EP EP12777430.5A patent/EP2701687B1/en active Active
- 2012-04-10 ES ES19176691T patent/ES2855349T3/es active Active
- 2012-04-10 AU AU2012248038A patent/AU2012248038B2/en active Active
- 2012-04-10 ES ES16179390T patent/ES2749864T3/es active Active
- 2012-04-10 BR BR112013027235-0A patent/BR112013027235B1/pt active IP Right Grant
- 2012-04-10 PT PT127774305T patent/PT2701687T/pt unknown
- 2012-04-10 US US14/113,738 patent/US9446135B2/en active Active
- 2012-04-10 EP EP19176691.4A patent/EP3566696B1/en active Active
- 2012-04-10 HU HUE16179390A patent/HUE046004T2/hu unknown
- 2012-04-10 PT PT161793906T patent/PT3199146T/pt unknown
- 2012-04-10 EP EP20199849.9A patent/EP3772354B1/en active Active
- 2012-04-10 PL PL12777430T patent/PL2701687T3/pl unknown
- 2012-04-10 RU RU2013147949/15A patent/RU2586306C2/ru active
- 2012-04-10 ES ES20199849T patent/ES2968917T3/es active Active
- 2012-04-10 KR KR1020157010621A patent/KR101932207B1/ko active IP Right Grant
- 2012-04-10 PL PL16179390T patent/PL3199146T3/pl unknown
- 2012-04-10 KR KR1020137029953A patent/KR101539313B1/ko active IP Right Grant
- 2012-04-10 ES ES12777430.5T patent/ES2607497T3/es active Active
- 2012-04-10 WO PCT/CN2012/000473 patent/WO2012146052A1/en active Application Filing
- 2012-04-10 PT PT191766914T patent/PT3566696T/pt unknown
- 2012-04-10 HU HUE19176691A patent/HUE052864T2/hu unknown
- 2012-04-10 CN CN201410314847.7A patent/CN104127385B/zh active Active
- 2012-04-10 EP EP16179390.6A patent/EP3199146B1/en active Active
- 2012-04-10 PL PL19176691T patent/PL3566696T3/pl unknown
- 2012-04-10 CN CN201280006994.7A patent/CN103338752B/zh active Active
- 2012-04-10 HU HUE12777430A patent/HUE032310T2/hu unknown
- 2012-04-10 PL PL20199849.9T patent/PL3772354T3/pl unknown
- 2012-04-10 JP JP2014506723A patent/JP5728128B2/ja active Active
-
2013
- 2013-11-21 HK HK13113031.9A patent/HK1185560A1/xx unknown
-
2015
- 2015-04-02 JP JP2015075711A patent/JP6072121B2/ja active Active
-
2016
- 2016-07-22 US US15/217,696 patent/US9532991B2/en active Active
- 2016-11-09 US US15/347,365 patent/US10098882B2/en active Active
-
2018
- 2018-09-27 US US16/144,614 patent/US10406161B2/en active Active
-
2019
- 2019-07-29 US US16/525,502 patent/US11110094B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1185560A1 (en) | Risperidone sustained release microsphere composition | |
| EP2637696A4 (en) | EXTENDED RELEASE COMPOSITION | |
| EP2714015A4 (en) | SOLID DOSAGE FORMS WITH CONTROLLED RELEASE | |
| EP2683668A4 (en) | HOLLOW MICROSPHERES | |
| ZA201306118B (en) | Lyophilized formulations | |
| EP2790729A4 (en) | PARTICULATE FORMULATIONS WITH DELAYED RELEASE | |
| ZA201202474B (en) | Controlled release compositions | |
| ZA201309653B (en) | Controlled release peptide formulations | |
| GB201102237D0 (en) | Particle formulation | |
| ZA201306016B (en) | Bendamustine formulations | |
| EP2554168A4 (en) | PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE | |
| EP2744496A4 (en) | FORMULATIONS WITH TAXED RELEASE | |
| ZA201308316B (en) | Sustained release paracetamol formulations | |
| EP2707338A4 (en) | PHOSPHOCOMENT WITH SLOW RELEASE | |
| HK1200738A1 (en) | Sustained release oral solid preparation | |
| GB201110278D0 (en) | Formulations | |
| HUP1100207A2 (en) | Modified release composition | |
| GB201016615D0 (en) | Drug release composition | |
| GB201111013D0 (en) | Formulations | |
| GB201107626D0 (en) | Formulations | |
| GB201107627D0 (en) | Formulations | |
| GB201105410D0 (en) | Formulations | |
| GB201105360D0 (en) | Formulations | |
| GB201104048D0 (en) | Formulations | |
| GB201104049D0 (en) | Formulations |